Evidence map›Paper›PMID 39693186›Full record

ArticleHuman vaccines & immunotherapeutics2024

Kounis syndrome following COVID-19 vaccination: Clinical manifestations, mechanisms and management.

Chengjie Zhao, Ruoyan Lei, Siyang Liu, Mingyi Zhao

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Kounis Syndrome Features in Special Populations.Medical sciences (Basel, Switzerland) · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chengjie ZhaoDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Ruoyan LeiDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Siyang LiuDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Mingyi ZhaoDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China.ORCID 0000-0002-2884-0736

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kounis syndrome is an acute coronary syndrome triggered by allergic mediators that induce coronary vasoconstriction and thrombosis, leading to further myocardial damage and anaphylactic shock. Kounis syndrome is also a rare but severe adverse reaction to the COVID-19 vaccine, a phenomenon that underscores the importance of collecting and analyzing similar cases to improve treatment and prognosis. Through comprehensive searches of the Web of Science, Embase, and PubMed databases, this study aimed to gather detailed patient data on patients who developed Kounis syndrome after receiving the COVID-19 vaccine and to further investigate the possible underlying mechanisms using currently available studies. A total of 15 patients (8 females, 7 males) were found. We analyzed comprehensive patient data, including demographics, vaccination details, time of onset of illness after vaccination, clinical manifestations, treatment and outcomes, duration of illness, and relevant examination results. Analysis of these data combined with known allergy-related mechanisms indicated that, regardless of the vaccine type, the first dose of the vaccine was more likely to cause Kounis syndrome than subsequent doses. Therefore, early diagnosis and clinical symptomatic treatment are particularly crucial for managing the severity of Kounis syndrome and preventing further cardiac complications. Additionally, when an unusual and severe allergic reaction occurs within a few hours after vaccination, it is important to closely monitor the development of cardiac-related symptoms and prepare clinically for the potential onset of Kounis syndrome.

Indexed as

COVID-19COVID-19 VaccinesKounis SyndromeAdultAgedFemaleHumansMaleMiddle AgedVaccinationCOVID-19 Vaccinesallergic reactionclinical manifestationCOVID-19Kounis syndromevaccines

Identifiers

PMID39693186
PMCPMC11188795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.